PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection |
|
|
| Completed | 2 | 63 | US | TNX-102 SL, Placebo SL Tablet | Tonix Pharmaceuticals, Inc. | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 07/23 | 07/23 | | |
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection |
|
|
| Completed | 2 | 63 | US | TNX-102 SL, Placebo SL Tablet | Tonix Pharmaceuticals, Inc. | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 07/23 | 07/23 | | |